HAE Haemonetics Corporation
Healthcare$66.84+2.06%ClosedMarket Cap: $3.04B
As of 2026-05-26
Valuation
P/E (TTM)
15.29
PEG
0.44
P/B
3.80
P/S
2.23
EV/EBITDA
11.72
DCF Value
$369.27
FCF Yield
8.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
57.3%
Operating Margin
18.2%
Net Margin
7.3%
ROE
11.3%
ROA
4.1%
ROIC
8.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 null | $346.4M | 57.2% | $51.4M | $-20.1M | $— | — |
| FY null | $1.33B | 55.7% | $241.4M | $97.3M | $— | — |
| Q3 null | $339.0M | 56.5% | $69.6M | $44.7M | $— | — |
| Q2 null | $327.3M | 56.0% | $67.3M | $38.7M | $— | — |
| Q1 null | $321.4M | 59.7% | $53.9M | $34.0M | $— | — |
| Q4 null | $330.6M | 55.0% | $51.5M | $58.0M | $— | — |
| FY null | $1.36B | 57.2% | $221.8M | $167.7M | $— | — |
| Q3 null | $348.5M | 57.4% | $59.0M | $37.5M | $— | — |
| Q2 null | $345.5M | 55.3% | $51.7M | $33.8M | $— | — |
| Q1 null | $336.2M | 53.3% | $39.8M | $38.4M | $— | — |
| Q4 null | $343.3M | 55.0% | $29.9M | $20.4M | $— | — |
| FY null | $1.31B | 54.4% | $164.9M | $117.6M | $— | — |